3. Ge, G., et al., Activation mechanism of solubilized epidermal growth factor receptor tyrosine kinase. Biochem Biophys Res Commun, 2002. 290(3): p. 914-20.
4. Spivak-Kroizman, T., et al., Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. J Biol Chem, 1992. 267(12): p. 8056-63.
5. Stoorvogel, W., et al., Sorting of ligand-activated epidermal growth factor receptor to lysosomes requires its actin-binding domain. J Biol Chem, 2004. 279(12): p. 11562-9.
6. Deng, W., et al., Optimal lysophosphatidic acid-induced DNA synthesis and cell migration but not survival require intact autophosphorylation sites of the epidermal growth factor receptor. J Biol Chem, 2004. 279(46): p. 47871-80.
7. Messerle, K., et al., NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant. Mol Cell Endocrinol, 1994. 105(1): p. 1-10.
8. Akiyama, T., et al., The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol, 1991. 11(2): p. 833-42.
9. Riese, D.J., 2nd, et al., The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol, 1995. 15(10): p. 5770-6.